Evidence map›Paper›PMID 38747315›Full record

ArticleAnnals of neurology2024

Cognitive Trajectories and Alzheimer Disease Biomarkers: From Successful Cognitive Aging to Clinical Impairment.

Theresa M Harrison, Trevor Chadwick, Stefania Pezzoli, JiaQie Lee, Susan M Landau, William J Jagust, Alzheimer's Disease Neuroimaging Initiative

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Annals of neurology, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed, 1 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed, 1 synthesis or guideline pooled it.

  1. Pooled it
  2. Review
  3. Article
  4. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

Theresa M HarrisonNeuroscience Department, University of California, Berkeley, Berkeley, CA, USA.ORCID 0000-0002-2036-3496
Trevor ChadwickNeuroscience Department, University of California, Berkeley, Berkeley, CA, USA.
Stefania PezzoliNeuroscience Department, University of California, Berkeley, Berkeley, CA, USA.
JiaQie LeeNeuroscience Department, University of California, Berkeley, Berkeley, CA, USA.
Susan M LandauNeuroscience Department, University of California, Berkeley, Berkeley, CA, USA.
William J JagustNeuroscience Department, University of California, Berkeley, Berkeley, CA, USA.ORCID 0000-0002-4458-113X
Alzheimer's Disease Neuroimaging Initiative

Funding

Alzheimer's Disease Neuroimaging Initiative - SupplementU01AG024904 · NIA · NORTHERN CALIFORNIA INSTITUTE RES &EDUC · PI WEINER, MICHAEL W · 2004 to 2015
$121.0M
Linking basal forebrain and entorhinal cortex vulnerability to preclinical Alzheimer's diseaseK01AG078443 · NIA · UNIVERSITY OF CALIFORNIA BERKELEY · PI Theresa M. Harrison · 2022 to 2026
$656k
Modeling Resilience to Alzheimer's Disease Pathology in Cognitively Healthy Older AdultsR03AG067033 · NIA · UNIVERSITY OF CALIFORNIA BERKELEY · PI HARRISON, THERESA M. · 2021 to 2021
$160k
Alzheimer's Association AARF-22-926053NIA NIH HHS K01 AG078443NIA NIH HHS K01AG078443NIA NIH HHS R03 AG067033NIA NIH HHS R03AG067033NIA NIH HHS U01 AG024904NIA NIH HHS U01AG024904
6 · The paper itself

Abstract

objectiveCross-sectional definitions of successful cognitive aging have been widely utilized, but longitudinal measurements can identify people who do not decline. We performed this study to contrast maintenance with declining trajectories, including clinical conversion.

methodsWe included baseline cognitively unimpaired Alzheimer's Disease Neuroimaging Initiative participants with 3 or more cognitive testing sessions (n = 539, follow-up 6.1 ± 3.5 years) and calculated slopes of an episodic memory composite (MEM) to classify them into two groups: maintainers (slope ≥ 0) and decliners (slope < 0). Within decliners, we examined a subgroup of individuals who became clinically impaired during follow-up. These groups were compared on baseline characteristics and cognitive performance, as well as both cross-sectional and longitudinal Alzheimer disease (AD) biomarker measures (beta-amyloid [Aβ], tau, and hippocampal volume).

resultsForty-one percent (n = 221) of the cohort were MEM maintainers, and 33% (n = 105) of decliners converted to clinical impairment during follow-up. Compared to those with superior baseline scores, maintainers had lower education and were more likely to be male. Maintainers and decliners did not differ on baseline MEM scores, but maintainers did have higher non-MEM cognitive scores. Maintainers had lower baseline global Aβ, lower tau pathology, and larger hippocampal volumes than decliners, even after removing converters. There were no differences in rates of change of any AD biomarkers between any cognitive trajectory groups except for a higher rate of hippocampal atrophy in clinical converters compared to maintainers.

interpretationUsing longitudinal data to define cognitive trajectory groups reduces education and sex bias and reveals the prognostic importance of early onset of accumulation of AD pathology. ANN NEUROL 2024;96:378-389.

Indexed as

Alzheimer DiseaseAmyloid beta-PeptidesBiomarkersCognitive AgingAgedAged, 80 and overCognitionCognitive DysfunctionCross-Sectional StudiesDisease ProgressionFemaleHippocampusHumansLongitudinal StudiesMaleMemory, EpisodicAmyloid beta-PeptidesBiomarkerstau Proteins

Identifiers

PMID38747315
PMCPMC11236492

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.